Journal Article

Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study – A complementary study

dos Santos, Maria Leticia Borges, da Conceição, Deborah Araújo, de Lourdes de Sousa Maia, Maria, Noronha, Tatiana Guimarães, Aguiar, Daniele Fernandes, Vianna, Clarice Monteiro, dos Santos, Eliane Matos, Xavier, Janaína Reis, de Lima, Sheila Maria Barbosa, Schwarcz, Waleska Dias, de Souza Cruz, Robson Leite, Homma, Akira, Camacho, Luiz Antonio Bastos, Andrade, Raissa Coelho, da Matta de Castro, Thalita, de Souza Azevedo Soares, Adriana, de Souza Brum, Ricardo Cristiano

2024

Overview

•A 2009 Bio-Manguinhos/Fiocruz YF vaccine dose–response study supported WHO's position for fractional dose for outbreaks.•Part of the original cohort was reassessed for immunity duration and seroconversion.•Seroconversion lasted 10 years.•Reduced doses have shown effective seroconversion (>80 %).•Antibody titers in reduced-dose versus full-dose groups remain equivalent. A single dose of standard yellow fever (YF) vaccine is considered to provide life-long protection. In this study, we evaluate the seropositivity conferred by lower doses 10 years post-vaccination. In 2009, Bio-Manguinhos/Fiocruz performed a dose–response study with the 17DD yellow fever vaccine, administering the vaccine in the usual mean dose of 27.476 IU and in decreasing doses (10.447 IU, 3.013 IU, 587 IU, 158 IU and 31 IU), with the usual volume and route (0,5 ml subcutaneous). The decreasing doses were obtained by dilution in the laboratory of the manufacturer and the lots in test had standard quality control and were produced by good manufacturing practices (GMP). Around 30 days after the vaccination, doses down to 587 IU had similar immunogenicity and the 158 IU and 31 IU were inferior to the full dose. The seropositivity was maintained for 10 months, except on the 31 IU group. Eight years after, 85 % of 318 participants evaluated in a follow-up, maintained seropositivity that was similar across groups. Consistently, antibody titers in the reduced-dose groups were also comparable to those of the full-dose group. The current study, 10 years later, showed similarity between the vaccine groups (six arms who received the YF vaccine in decreasing doses: 27.476 IU, 10.447 IU, 3.013 IU, 587 IU, 158 IU, 31 IU) both in relation of seropositivity and in the evaluation of the geometric mean titers. The seropositivity rates across subgroups were 83,1%, 90 %, 87 %, 93 %, 83,8% and 85 %, correspondingly. These findings provides further support to the long-term immunogenicity of lower doses. Clinical trial registry: NCT04416477.

• Publisher: Elsevier Ltd,Elsevier Limited,Elsevier Science
• Subject: 17DD vaccine / Adult / Adults / Allergy and Immunology / antibodies / Antibodies, Viral - blood / Antibodies, Viral - immunology / clinical trials / Clinical Trials as Topic / Cross-Sectional Studies / Dilution / dose response / Dose-Response Relationship, Immunologic / Dose–response study / Epidemics / Epidemiology / Fever / Follow-Up Studies / Healthy Volunteers / Humans / Immunity (Disease) / Immunogenicity / Immunogenicity, Vaccine / Infectious diseases / Male / Mosquitoes / Quality control / seroprevalence / Shortages / Subgroups / Time Factors / vaccination / Vaccination - methods / Vaccines / Vector-borne diseases / Yellow fever / Yellow Fever - immunology / Yellow Fever - prevention & control / Yellow Fever Vaccine - administration & dosage / Yellow Fever Vaccine - immunology / Yellow fever virus - immunology / Young Adult